Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T specialist Kyverna and private rounds for Eyconis, COUR Pharmaceuticals, Basking Biosciences, Enterprise Therapeutics, Halia Therapeutics and NeoPhore..

我们最近对生物技术融资的总结是，为晚期临床阶段的生物技术Vera Therapeutics进行了2.5亿美元的公开募股，由CAR-T专家Kyverna提交了首次公开募股（IPO），并为Eyconis，COUR Pharmaceuticals，Basking Biosciences，Enterprise Therapeutics，Halia Therapeutics和NeoPhore进行了私人募股。。

The underwritten offering of common stock at $31 per share comes shortly after Brisbane, California-based Vera Therapeutics reported new 72-week data from an open-label extension of the phase 2b ORIGIN trial of ataticept which backed up the role of the drug as a possible treatment for IgA nephropathy (IgAN), a rare disease in which antibodies accumulate in the kidneys, causing inflammation and scarring.

在以每股31美元的价格承销普通股之前不久，总部位于加利福尼亚州布里斯班的维拉治疗公司（Vera Therapeutics）报告了来自ataticept 2b期ORIGIN试验的开放标签扩展的新72周数据，该试验支持该药物作为治疗IgA肾病（IgAN）的可能药物的作用，IgA肾病是一种罕见的疾病，抗体在肾脏中积累，引起炎症和疤痕。

It affects around 150,000 people in the US alone and can develop into chronic kidney disease (CKD)..

它仅在美国就影响了大约150000人，并可能发展为慢性肾病（CKD）。。

The subcutaneously administered drug, a dual inhibitor of the cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), is vying to become the first self-administered B-cell modulation therapy and is in a phase 3 trial (ORIGIN 3) due to generate results in the first half of next year.

这种皮下给药的药物是细胞因子B细胞活化因子（BAFF）和增殖诱导配体（APRIL）的双重抑制剂，正争相成为第一种自我给药的B细胞调节疗法，目前正在进行3期试验（ORIGIN 3），预计明年上半年会产生结果。

In the phase 2b ORIGIN trial, ataticept was able to stabilise the estimated glomerular filtration rate (eGFR), a measure of how well the kidneys are working, which Vera says is “unprecedented” in IgAN therapeutics development. LifeSci Capital is acting as the lead manager for the proposed offering..

在2b期ORIGIN试验中，阿塔西普能够稳定估计的肾小球滤过率（eGFR），这是衡量肾脏工作状况的指标，维拉说这在IgAN治疗学的发展中是“前所未有的”。LifeSci Capital担任拟议发售的首席管理人。。

In another sign that the biotech IPO market is picking up, cell therapy specialist Kyverna has filed to raise roughly $211 million from the sale of around 11 million shares at between $17 and $19 each, above its earlier expectations. The proceeds will help to fund its lead CAR-T product candidate, KYV-101, as it moves through clinical development for rheumatological and autoimmune diseases including lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis..

另一个表明生物技术IPO市场正在回暖的迹象是，细胞治疗专家凯弗纳（Kyverna）申请从1100万股左右的股票中融资约2.11亿美元，每股价格在17美元至19美元之间，高于此前的预期。这些收益将有助于资助其主要的CAR-T候选产品KYV-101，因为它正在进行风湿病和自身免疫性疾病的临床开发，包括狼疮性肾炎、系统性硬化症、重症肌无力和多发性硬化症。。

Emeryville, California-based Kyverna was founded in 2018 and is one of several companies aiming to extend the use of CAR-T therapies beyond cancer. It plans to list on the Nasdaq under the KYTX ticker, with the IPO expected to price sometime next week.

总部位于加利福尼亚州埃默里维尔的Kyverna成立于2018年，是几家旨在将CAR-T疗法的使用扩展到癌症之外的公司之一。该公司计划以KYTX股票代码在纳斯达克上市，IPO预计将于下周某个时候定价。

Brand new biotech Eyconis, a spinout set up to advance the ophthalmology assets of Denmark’s Ascendis Pharma in collaboration Frazier Life Sciences, has started its life with $150 million in capital from a syndicate that included Frazier, RA Capital Management, venBio, and HealthQuest Capital.

全新的biotech Eyconis是丹麦Ascendis Pharma与Frazier Life Sciences合作开发眼科资产的一家分支机构，它从一个财团（包括Frazier、RA capital Management、venBio和HealthQuest capital）获得的1.5亿美元资金开始运作。

Eyconis will initially be based in Redwood City, California, and has been granted rights to Ascendis’ ophthalmology products, including a preclinical-stage candidate for age-related macular degeneration (AMD), a leading cause of blindness, that could be dosed just twice a year. The candidate, called Transcon RBZ, is a hydrogel formulation of ranibizumab, the active ingredient in Roche and Novartis’ blockbuster AMD therapy Lucentis which is now facing biosimilar competition.

Eyconis最初将位于加利福尼亚州红木市，并已获得Ascendis眼科产品的使用权，其中包括一种与年龄相关的黄斑变性（AMD）的临床前候选药物，AMD是导致失明的主要原因，每年只能服用两次。该候选药物名为Transcon RBZ，是雷尼珠单抗的水凝胶制剂，雷尼珠单抗是罗氏和诺华的重磅AMD治疗药物Lucentis的活性成分，目前正面临生物仿制药竞争。

.

.

COUR Pharmaceuticals attracted no fewer than three big pharma backers for its $107 million Series A, with the VC funds of Roche, Pfizer and Bristol-Myers Squibb joining Angelini Ventures and the JDRF T1D Fund in a round led by Lumira Ventures and Alpha Wave Ventures.

COUR Pharmaceuticals以其1.07亿美元的A系列吸引了不少于三家大型制药公司的支持者，罗氏（Roche）、辉瑞（Pfizer）和百时美施贵宝（Bristol-Myers Squibb）的风险投资基金加入了Angelini Ventures和JDRF T1D基金，由Lumira Ventures和Alpha Wave Ventures牵头。

The funds will be used to support the advancement of the Chicago biotech’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into phase 2a proof-of-concept trials. COUR’s antigen-specific immune tolerance platform is based on nanoparticles that bind to monocyte immune cells and deliver an antigen payload.

这些资金将用于支持芝加哥生物技术公司的重症肌无力（MG）和1型糖尿病（T1D）候选产品进入2a期概念验证试验。COUR的抗原特异性免疫耐受平台基于与单核细胞免疫细胞结合并提供抗原有效载荷的纳米颗粒。

The company has also signed two partnerships with other pharma partners, with Takeda in coeliac disease and Ironwood Pharma in primary biliary cholangitis..

该公司还与其他制药合作伙伴签署了两项合作协议，分别是治疗乳糜泻的武田和治疗原发性胆汁性胆管炎的铁木制药。。

Columbus, Ohio-based startup Basking Biosciences has raised $55 million in an unspecific round that will be used to fund a phase 2 trial of BB-031, described as a first-in-class RNA aptamer targeting von Willebrand Factor (vWF) that is intended to treat acute ischaemic stroke. The drug is designed to have a rapid onset and short duration of action, dissolving clots quickly and minimising the risk of bleeding side effects, with the potential for use beyond the current window of opportunity for current thrombolytic therapies.

总部位于俄亥俄州哥伦布的初创公司Basking Biosciences在一轮非特异性融资中筹集了5500万美元，将用于资助BB-031的第二阶段试验，该试验被描述为针对von Willebrand因子（vWF）的一流RNA适体，旨在治疗急性缺血性中风。该药起效快，作用时间短，能迅速溶解凝块，并将出血副作用的风险降至最低，有可能在目前溶栓治疗的机会窗口之外使用。

Basking is also working on a reversal agent (BB-025) to switch off its effects if needed..

Basking还在研究一种逆转剂（BB-025），如果需要的话，可以关闭它的效果。。

New investor ARCH Venture Partners led the round, with participation from additional new investors Insight Partners, Platanus, Solas BioVentures and RTW Investments, as well as existing investors Longview Ventures, Rev1 Ventures and The Ohio State University.

新投资者ARCH Venture Partners领导了这一轮投资，其他新投资者Insight Partners、Platanus、Solas BioVentures和RTW Investments以及现有投资者Longview Ventures、Rev1 Ventures和俄亥俄州立大学也参与了这一轮投资。

UK biotech Enterprise Therapeutics has closed a £26 million ($33 million) Series B follow-on round led by new investor Panakes that will be used for a phase 2a clinical proof of concept trial in cystic fibrosis for ETD001, an ENaC blocker designed to help clear mucus from the lungs of patients with the disease..

英国生物技术企业治疗公司（UK biotech Enterprise Therapeutics）结束了由新投资者Panakes领导的2600万英镑（3300万美元）B系列后续回合，该轮后续回合将用于ETD001囊性纤维化的2a期临床概念验证试验，ETD001是一种ENaC阻滞剂，旨在帮助清除该病患者肺部的粘液。。

Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated in the round, which will also go towards expanding the Brighton-based company’s pipeline of low-molecular-weight compounds targeting the underlying mechanisms of mucus congestion.

现有投资者Versant Ventures、Novartis Venture Fund、Forbion、Epidarex Capital和IP Group也参与了这轮投资，这也将致力于扩大位于布莱顿的公司针对粘液堵塞潜在机制的低分子量化合物管道。

Utah-based Halia Therapeutics has completed a $30 million Series C financing for its pipeline of small-molecule drugs led by HT-6184, which targets NLRP3 – an immune sensor protein complex or ‘inflammasome’ that when activated triggers the release of the pro-inflammatory cytokines. The financing was led by Todd Pedersen – a Utah entrepreneur and founder of the Vivint smart home device company – with additional participation from existing investors.

总部位于犹他州的Halia Therapeutics为其以HT-6184为首的小分子药物管道完成了3000万美元的C系列融资，该药物靶向NLRP3，NLRP3是一种免疫传感器蛋白复合物或“炎性体”，激活后会触发促炎细胞因子的释放。此次融资由犹他州企业家、Vivint智能家居设备公司创始人托德·佩德森（ToddPedersen）牵头，现有投资者也参与了此次融资。

HT-6184 inhibits the NEK7 component of NLRP3 and is in a phase 2a trial in India as a treatment for lower-risk myelodysplastic syndromes (MDS), a form of blood cancer. In the US, the Lehi-based company is planning a phase 2 trial in post-procedure inflammatory pain response and a phase 1 in Alzheimer’s disease..

HT-6184抑制NLRP3的NEK7成分，目前正在印度进行2a期试验，用于治疗低风险骨髓增生异常综合征（MDS），一种血癌形式。在美国，这家总部位于Lehi的公司正在计划进行术后炎症性疼痛反应的2期试验和阿尔茨海默病的1期试验。。

Finally this week, London, UK-based NeoPhore completed a follow-on Series B financing that raised an additional £9.6 million ($12.2 million), taking the total raised to more than £31 million. NeoPhore is building a pipeline of small-molecule drugs that inhibit proteins in the DNA mismatch repair (MMR) pathway, inducing neoantigen expression by tumour cells so they can be targeted by the immune system.

最后，本周，总部位于英国伦敦的NeoPhore完成了后续的B系列融资，额外筹集了960万英镑（1220万美元），使募集资金总额超过3100万英镑。NeoPhore正在建立一条小分子药物管道，这些药物可以抑制DNA错配修复（MMR）途径中的蛋白质，诱导肿瘤细胞表达新抗原，从而可以被免疫系统靶向。

Its lead candidate is in preclinical development..

其主要候选人正在临床前开发中。。

The round saw new Italian investors NEVA SGR, LIFTT and Simon Fiduciaria join the existing group of CPF (Sixth Element Capital), Claris Ventures, Astellas Venture Management, 3B Future Health Fund, and 2investAG.

新的意大利投资者NEVA SGR、LIFTT和Simon Fiduciaria加入了现有的CPF（第六要素资本）、Claris Ventures、Astellas Venture Management、3B Future Health Fund和2investAG集团。

Photo by Towfiqu barbhuiya on Unsplash

Towfiqu barbhuiya在Unsplash上的照片